R

Ranbaxy Laboratories Ltd (Merged)

RANBAXY NSE
This stock has been delisted or merged and is no longer actively traded.

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Debtor days have improved from 74.3 to 57.0 days.

Weaknesses

3
  • Stock is trading at 9.99 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 9.16% over last 3 years.

Growth Rate

Revenue Growth
0% lower than 3Y
Net Income Growth
-157%

Quarterly Results

Particulars Dec 2011Mar 2012Jun 2012Sep 2012Dec 2012Mar 2013Jun 2013Sep 2013Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014
Sales
3,826
3,781
3,259
2,708
2,711
2,472
2,634
2,802
2,894
2,467
2,416
3,260
2,619
Expenses
3,028
2,690
2,998
2,372
2,658
2,317
2,511
2,602
2,624
2,413
2,286
2,555
2,506
Operating Profit
798
1,091
261
336
53
155
123
199
270
54
130
705
113
OPM %
21%
29%
8%
12%
1.9%
6%
4.7%
7%
9%
2.2%
5%
22%
4.3%
Other Income
-3,443
405
-530
459
-289
144
-451
-346
-119
89
-181
-5
-5
Interest
91
19
165
-16
136
53
159
111
121
114
142
137
147
Depreciation
168
80
78
0
80
80
0
133
92
0
0
0
97
PBT
-2,903
1,398
-512
811
-453
167
-487
-391
-60
30
-192
563
-135
Tax %
3%
10%
13%
7%
8%
21%
6%
15%
163%
371%
-3%
15%
656%
Net Profit
-2,980
1,248
-584
757
-489
130
-523
-453
-162
-79
-189
477
-1,024
EPS in Rs
-70.68
29.54
-13.88
17.86
-11.64
2.97
-12.39
-10.73
-3.75
-1.74
-4.39
11.27
-24.23
Figures in ₹ Crores

Profit & Loss

Particulars Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014 15mTTM
Sales
5,134
6,057
6,684
7,296
7,515
8,876
10,315
12,452
13,259
10,762
Expenses
5,022
5,276
6,143
8,756
6,924
7,806
8,861
10,647
12,281
9,760
Operating Profit
112
781
540
-1,460
591
1,070
1,455
1,805
977
1,002
OPM %
2.2%
13%
8%
-20%
8%
12%
14%
14%
7%
9%
Other Income
259
123
771
448
758
1,463
-3,441
64
-686
-100
Interest
67
104
141
206
71
61
306
304
557
540
Depreciation
109
149
172
282
268
372
394
320
476
97
PBT
194
651
999
-1,500
1,010
2,100
-2,686
1,245
-742
265
Tax %
-36%
21%
21%
-38%
69%
28%
7%
24%
45%
—
Net Profit
264
515
787
-943
307
1,509
-2,890
932
-1,087
-815
EPS in Rs
—
13.69
20.76
-22.63
7.05
35.55
-68.71
21.82
-25.61
-19.09
Div. Payout %
121%
62%
41%
0%
0%
6%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014
Equity Capital
186
186
187
210
210
211
211
211
212
Reserves
2,261
2,400
2,617
4,086
4,133
5,394
2,658
3,873
3,091
Borrowings
2,004
3,956
4,142
4,285
3,630
4,335
4,491
4,901
6,598
Other Liabilities
1,517
1,891
2,333
4,656
4,165
4,205
8,352
7,466
4,077
Total Liabilities
5,969
8,432
9,278
13,237
12,137
14,144
15,712
16,452
13,978
Fixed Assets
2,059
3,895
4,205
4,490
4,490
4,548
4,830
5,008
5,081
CWIP
560
358
357
471
623
382
227
208
303
Investments
17
36
240
543
541
498
98
79
72
Other Assets
3,333
4,143
4,476
7,733
6,483
8,716
10,557
11,157
8,522
Total Assets
5,969
8,432
9,278
13,237
12,137
14,144
15,712
16,452
13,978
Figures in ₹ Crores

Cash Flow

Particulars Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014
Operating
204
529
1,023
-152
-162
1,539
639
1,582
-3,562
Investing
-838
-1,993
-841
-1,776
54
-2,196
1,781
-1,871
1,958
Financing
746
1,513
-39
2,676
-522
791
-1,218
237
1,016
Net Cash Flow
112
49
143
749
-631
134
1,202
-52
-588
Free Cash Flow
-704
109
587
-586
-653
1,112
190
1,117
-4,335
CFO/OP
213
59
215
1
14
202
59
105
-323
Figures in ₹ Crores

Ratios

Particulars Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Mar 2014
Debtor Days
81
95
82
67
89
66
106
60
57
Inventory Days
224
248
220
234
219
266
286
246
209
Days Payable
127
130
116
133
171
230
156
146
111
Cash Conversion Cycle
178
213
186
168
137
102
236
159
154
Working Capital Days
113
124
104
-24
32
53
1
-18
56
ROCE %
—
14%
16%
-18%
12%
21%
15%
21%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Ranbaxy Laboratories Ltd (Merged) insights

58 extracted metrics + investor summaries across FY05–FY14.

Log in — free

Documents

Frequently Asked Questions about Ranbaxy Laboratories Ltd (Merged)

What does Ranbaxy Laboratories Ltd (Merged) do?
Ranbaxy Laboratories Limited,Incorporated in India, listed on the Bombay Stock Exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceutical
Where is Ranbaxy Laboratories Ltd (Merged) (RANBAXY) listed?
Ranbaxy Laboratories Ltd (Merged) trades as RANBAXY on the NSE.
Which sector does Ranbaxy Laboratories Ltd (Merged) belong to?
Ranbaxy Laboratories Ltd (Merged) is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.

Company Information

Ranbaxy Laboratories Limited,Incorporated in India, listed on the Bombay Stock Exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceutical

Website ranbaxy.com
Face Value ₹ 5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/RANBAXY.md for Ranbaxy Laboratories Ltd (Merged): company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List